A61K49/04

Radiopaque dental composition

The invention relates to a radiation-curable radiopaque dental composition comprising a resin matrix comprising cross-linkable component(s) as Component A, ethylenically unsaturated component(s) with acidic moiety as Component B, an initiator system comprising photoinitiator(s) as Component C, reducing agent(s) as Component D, Component A containing at least two (meth)acrylate moieties and a brominated aromatic moiety selected from brominated resorcinol, catechol, tyrosol, benzoic acid, or phenol moieties. The composition can be used for producing an x-ray visible dental adhesive composition, restoration primer or dental sealant.

Radiopaque dental composition

The invention relates to a radiation-curable radiopaque dental composition comprising a resin matrix comprising cross-linkable component(s) as Component A, ethylenically unsaturated component(s) with acidic moiety as Component B, an initiator system comprising photoinitiator(s) as Component C, reducing agent(s) as Component D, Component A containing at least two (meth)acrylate moieties and a brominated aromatic moiety selected from brominated resorcinol, catechol, tyrosol, benzoic acid, or phenol moieties. The composition can be used for producing an x-ray visible dental adhesive composition, restoration primer or dental sealant.

PHARMACEUTICAL PREPARATION WITH TRACING FUNCTION AND DELIVERY SYSTEM THEREFOR
20230089830 · 2023-03-23 · ·

Disclosed are a pharmaceutical preparation with a tracing function, and a delivery system therefor. The pharmaceutical preparation comprises a first drug and a second drug in a liquid or gaseous state, wherein the first drug and the second drug are each divided into multiple sections, which are arranged in series at intervals in a conduit. One of the first drug and the second drug is a tracer drug that can be developed in a medical imaging device in the human body. The first drug and the second drug are immiscible and satisfy compatibility requirements. The pharmaceutical preparation can comprise an aerobic contrast agent, an aerobic embolic agent and an aerobic perfusion agent. Same can be applied to a variety of contrast techniques by means of a one-step simple operation, saving the dosage of a drug while maintaining a high concentration of the drug.

DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE

The present invention relates to a composition comprising non-water soluble dissacharides and oil, a solvent and at least one pharmaceutical ingredient, wherein the composition contains at least two compounds selected from saccharides and lipid oils such as lactose octabenzoate Methyl hepta-O-isobutyryl-α,β-lactoside, α,β-Lactose octa para-iodobenzoate, 3-iodobenzyl hepta-O-isobutyryl-α,β-lactoside, lactose octapropionate, lactose octaisobutyrate, sucrose octabenzoate, glycerol trihexanoate, Glycerol trioctanoate, Glycerol tridecanoate, Lipiodol, ethyl myristate, ethyl palmitate, ethyl oleoate and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 2,000 centipoise (cP) after administration.

VEGETABLE OIL-DERIVED CONTRAST AGENT WITH HIGH STABILITY AND PREPARATION METHOD THEREOF
20220339299 · 2022-10-27 ·

Proposed are a contrast agent containing an iodinated unsaturated fatty acid ethyl ester derived from vegetable oil, a non-iodinated unsaturated fatty acid ethyl ester, and sulfur dioxide (SO.sub.2), and a production method thereof. The contrast agent having a similar contrast effect is synthesized using vegetable oil as a substitute for poppy seed oil, which is unstable in terms of supply and is expensive. In addition, the long-term stability problem of an iodine-based contrast agent is solved by adding a non-iodinated unsaturated fatty acid ethyl ester and sulfur dioxide.

IODINE LABELED HYDROGELS AND PRECURSORS THEREOF WITH IMPROVED RADIOPACITY

In some embodiments, the present disclosure pertains to systems for forming a hydrogel that comprise (a) a first composition that comprises a polyiodinated polyamino compound and (b) a second composition that comprises a reactive multi-arm polymer that comprises a plurality of hydrophilic polymer arms having reactive end groups that are reactive with the amino groups of the polyiodinated polyamino compound. In some embodiments, the present disclosure pertains to medical hydrogels that are formed by reacting a polyiodinated polyamino compound and a reactive multi-arm polymer that comprises a plurality of hydrophilic polymer arms having reactive end groups that are reactive with the amino groups of the polyiodinated polyamino compound. In some embodiments, the present disclosure pertains to methods of making polyiodinated polyamino compounds.

Curcumin-based magnetic nanostructured system for dual response of imaging and therapeutics

Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.

CURCUMINOID CHEMOTHERAPEUTIC DRUG CARRIER COMPOSITION

Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.

Nanoemulsion of iodinated fatty acids for CT imaging

An iodinated CT contrast agent made of fatty acid derivatives for non-invasive visualisation and quantification of the brown and/or beige adipose tissue (BAT) or for imaging the heart and/or liver of a subject, to be taken orally which is a breakthrough in CT imaging. Image resolution by CT is significantly enhanced compared to PET.

Method and Apparatus for Optimizing the Use of Contrast Agents during Medical Imaging
20220327706 · 2022-10-13 ·

A method of establishing a quantitative measure of contrast enhancement in contrast medical imaging through computer analysis of baseline and enhanced images allows statistical comparison of protocols and imaging parameters from routine hospital operations to enhance and evaluate such protocols and parameters.